Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Declines By 98.0%

Posted by Geri Gentry on May 27th, 2026

GlucoTrack, Inc. (NASDAQ:GCTK – Get Free Report) was the recipient of a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 44,035 shares, a decline of 98.0% from the April 30th total of 2,166,796 shares. Based on an average trading volume of 9,850,067 shares, the short-interest ratio is presently 0.0 days. Approximately 0.7% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

View Our Latest Stock Report on GlucoTrack

GlucoTrack Trading Up 8.0%

GCTK stock traded up $0.05 during trading on Wednesday, reaching $0.64. 1,596,492 shares of the stock traded hands, compared to its average volume of 10,925,522. The business’s 50 day moving average price is $0.78 and its 200-day moving average price is $2.62. GlucoTrack has a 52-week low of $0.43 and a 52-week high of $15.90. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.85 and a quick ratio of 0.85. The firm has a market capitalization of $3.99 million, a PE ratio of -0.04 and a beta of 0.78.

Institutional Investors Weigh In On GlucoTrack

Several institutional investors and hedge funds have recently modified their holdings of GCTK. Bank of America Corp DE boosted its position in shares of GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after buying an additional 4,085 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of GlucoTrack in the fourth quarter worth about $52,000. Finally, Ikarian Capital LLC purchased a new stake in shares of GlucoTrack in the fourth quarter worth about $177,000. Hedge funds and other institutional investors own 10.92% of the company’s stock.

About GlucoTrack

(Get Free Report)

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.

Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.